Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …

Tyrosine kinase inhibitors of the epidermal growth factor receptor, gefitinib and erlotinib,
have changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) …

Background: This meta-analysis evaluated the efficacy and toxicity of gefitinib with other
commonly used drugs in different treatment settings and epidermal growth factor receptor …

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Introduction Inhibition of the epidermal growth factor receptor is a promising therapy in the
treatment of non-small cell lung cancer (NSCLC). In this systematic review, we evaluated the …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been
extensively investigated in previously treated advanced non-small-cell lung cancer …

This study aimed to perform a meta-analysis comparing the efficacy and safety of gefitinib in
combination with chemotherapy versus gefitinib alone in patients with advanced Non-Small …

7551 Background: Gefitinib and erlotinib are potent inhibitors of the epidermal growth factor
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …